✦ LIBER ✦

Quantitative histopathology and chromosome 9 polysomy in a clinical trial of 4-HPR

✍ Scribed by Jose-Miguel Yamal; Dennis Cox; Walter N Hittelman; Iouri Boiko; Anais Malpica; Martial Guillaud; Calum MacAulay; Michele Follen; Anne-Therese Vlastos

Book ID: 113959331
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 970 KB
Volume: 94
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2004.04.030

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cervical chromosome 9 polysomy: Validati

Cervical chromosome 9 polysomy: Validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial

✍ Heung Gon Kim; Jose-Miguel Yamal; Xiao-Chun Xu; Wei Hu; Iouri Boiko; Adriana Lin 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 202 KB

Difficulties in Precise Quantitation of

Difficulties in Precise Quantitation of CD4+ T Lymphocytes for Clinical Trials: A Review

✍ David T.W. Fei; Helene Paxton; Anthony B. Chen 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 691 KB

A pericentric inversion of chromosome 9

A pericentric inversion of chromosome 9 and a rearrangement involving chromosomes 9 and 10, observed in two generations. Clinical description of chromosome 9 (p12-p21) deletion syndrome

✍ S. P. Fällstrom; J. Wahlström 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 604 KB

Determination of HER-2 Status and Chromo

Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH Assay

✍ Varshney, Dolly; Zhou, Yvonne Y.; Geller, Stephen A.; Alsabeh, Randa 📂 Article 📅 2004 🏛 American Society for Clinical Pathology 🌐 English ⚖ 103 KB

Population studies of inv(9) chromosomes

Population studies of inv(9) chromosomes in 4,300 japanese: Incidence, sex difference and clinical significance

✍ Kiyomi Yamada 📂 Article 📅 1992 🏛 Nature Publishing Group 🌐 English ⚖ 566 KB

The clinical pharmacokinetics of N-5-dim

The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in a phase 1 trial

✍ J. W. Paxton; J. R. Hardy; P. C. Evans; V. J. Harvey; B. C. Baguley 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 528 KB

The pharmacokinetics of CI-921 were studied after 65 infusions over a 20-fold dose range (13-270 mg/m2 per day) in 16 patients during a phase 1 trial. CI-921 was given by a 15 min infusion on three consecutive days. Plasma samples were collected after the first and third infusions, and urine, at 6 h